Uncertainties Threaten Venture-Capital-Backed Device Firms, MDMA Says
This article was originally published in The Gray Sheet
Executive Summary
Policy-makers can protect device manufacturers' access to venture capital by tackling regulatory uncertainties that interfere with VC firms' exit strategies, according to a report by the Medical Devices Manufacturers Association and the National Venture Capital Association
You may also be interested in...
MDMA venture capital report
The Medical Device Manufacturers Association and National Venture Capital Association release a joint 1report on protecting the "fragile" med-tech/venture capital landscape. The report, previewed in February, addresses industry concerns about comparative effectiveness research, pending patent reform legislation, reimbursement and the FDA approval process, which have the potential to impede venture capital investment in device start-ups (2"The Gray Sheet" March 2, 2009, p. 14). In 2008, venture capitalists invested just under $3.5 billion in device firms, down from more than $4 billion in 2007, the report notes
MDMA venture capital report
The Medical Device Manufacturers Association and National Venture Capital Association release a joint 1report on protecting the "fragile" med-tech/venture capital landscape. The report, previewed in February, addresses industry concerns about comparative effectiveness research, pending patent reform legislation, reimbursement and the FDA approval process, which have the potential to impede venture capital investment in device start-ups (2"The Gray Sheet" March 2, 2009, p. 14). In 2008, venture capitalists invested just under $3.5 billion in device firms, down from more than $4 billion in 2007, the report notes
Venture Capital For MedTech “Somewhat Resilient,” With 18% Drop In ’08
The U.S. medical technology industry's access to private venture capital remained relatively strong in 2008, while its ability to raise funds through debt and public stock offerings took a beating from the global financial crisis, according to a recent 1report by consulting firm Ernst & Young